<DOC>
	<DOCNO>NCT00307658</DOCNO>
	<brief_summary>The aim study study efficacy intravenous immunoglobulin induce remission patient relapse systemic vasculitides .</brief_summary>
	<brief_title>Intravenous Immunoglobulin After Relapse Vasculitis</brief_title>
	<detailed_description>The aim study assess effect intravenous immunoglobulin ANCA+ vasculitides ( Microscopic Polyangiitis , Wegener ’ granulomatosis Churg-Strauss syndrome ) relapse corticosteroid immunosuppressant therapy one year post treatment .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Wegener ’ granulomatosis , Microscopic polyangiitis ChurgStrauss syndrome ( satisfy ACR chapel Hill classification ) relapse either corticosteroid immunosuppressant therapy one year post treatment Age &gt; 18 year old Written inform consent Systemic vasculitides previously treat corticosteroid immunosuppressant ( ) Systemic vasculitides treat corticosteroid immunosuppressant therapy , treatment cessation 12 month ago Polyarteritis nodosa Absence poor prognosis criterion ( accord FFS ) Nephritis ± renal impairment Cancer malignancy Psychiatric disease , lack compliance Age 18 year old Lack write informed consent Other vasculitides ( post viral infection skin localisation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>ANCA associate Vasculitides</keyword>
	<keyword>Relapse</keyword>
	<keyword>intravenous Immunoglobulins</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Immunosuppressant</keyword>
</DOC>